Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02558348 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
A Phase 1 study, sponsored by Advenchen Laboratories.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02558348 is a Phase 1 study that was terminated before completion, run by Advenchen Laboratories. The registered enrollment target is 12 participants.
The verdict
NCT02558348, a Phase 1 study, was terminated before completion, sponsored by Advenchen Laboratories.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of Part 1 (Phase 1b) is to evaluate the general safety and tolerability of repeated 21-day cycles of AL3818 therapy, and to reevaluate the maximum tolerated dose (MTD). The purpose of Part 2 (Phase 2a) is to evaluate the efficacy of repeated 21-day cycles of AL3818 therapy preliminary efficacy of AL3818 in subjects with recurrent or metastatic endometrial, ovarian or cervical cancer.
Interventions
- DRUG AL3818
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02558348
The ClinicalTrials.gov registry entry for NCT02558348 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advenchen Laboratories, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AL3818 is the first listed.
NCT02558348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02558348 about?
NCT02558348 is a clinical study titled "Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)". The purpose of Part 1 (Phase 1b) is to evaluate the general safety and tolerability of repeated 21-day cycles of AL3818 therapy, and to reevaluate the maximum tolerated dose (MTD). The purpose of Part 2 (Phase 2a) is to evaluate the efficacy of repeated 21-day cycles of AL3818 therapy preliminary e...
What is the current status of trial NCT02558348?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-11. Estimated completion is 2017-05-30.
What interventions are being tested in trial NCT02558348?
The interventions under investigation include: AL3818 (DRUG).
Who is sponsoring clinical trial NCT02558348?
This trial is sponsored by Advenchen Laboratories, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.